pTau181, which is closely correlated with total tau levels in CSF, is markedly elevated in AD but not in most other neurodegenerative conditions, making it the gold standard for assessing phosphorylated tau levels and an AD-specific marker (Skillback et al., 2015). This evidence concerns the gene MAPT and Alzheimer disease.